Symbiotec Pharmalab Ltd

Thu 8/10/2026,15:59:20 | NSE : SYMBIOTEC

₹1093.80-41.80 (-3.68%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1130.00

Previous Close

₹ 1135.60

Volume

645045

Mkt Cap ( ₹ Cr)

₹ 7028.33

High

₹ 1143.00

Low

₹ 1080.70

52 Week High

₹ 1246.00

52 Week Low

₹ 934.20

Book Value Per Share

₹ 178.98

Dividend Yield

0.00

Face Value

₹ 2.00

What's Your Call?

Collective community sentiment on Symbiotec Pharmalab Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1093.80

108

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

108

Option Chain

Analyzes market sentiment, predicts Symbiotec Pharmalab Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Symbiotec Pharmalab - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    5 Oct 2026, 5:46PM Symbiotec Pharmalab Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter e
  • Symbiotec Pharmalab - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    5 Oct 2026, 5:39PM Certificate Pursuant to regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026.
  • Symbiotec Pharmalab - General Updates

    30 Sep 2026, 8:20PM Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategiccommercialization agreement with a leading global pharmaceutical compan
  • Symbiotec Pharmalab - General Updates

    30 Sep 2026, 8:16PM Symbiotec Pharmalab Limited has informed the Exchange about General Updates
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Trading Window

    29 Sep 2026, 12:19PM Symbiotec Pharmalab Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio
  • Symbiotec Pharmalab - General Updates

    29 Sep 2026, 10:58AM Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection Report (""EIR"") From U.S. FDA for Its Manufactu
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection R

    29 Sep 2026, 10:52AM Symbiotec Pharmalab Limited receives Establishment Inspection Report (\EIR\) from U.S. FDA for its manufacturing facility in Pithampur (\SEZ\) with VA
  • Symbiotec Pharmalab - Analysts/Institutional Investor Meet/Con. Call Updates

    28 Sep 2026, 6:36PM Symbiotec Pharmalab Limited has informed the Exchange about Transcript
  • Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    28 Sep 2026, 6:29PM Transcript of the Earnings conference call for Analysts and Investors for Q1 Financial Year 2027
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre

    30 Sep 2026, 8:09PM Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical compa
  • Symbiotec Pharmalab - Analysts/Institutional Investor Meet/Con. Call Updates

    22 Sep 2026, 2:43PM Symbiotec Pharmalab Limited has informed the Exchange about Link of Recording
  • Symbiotec Pharmalab - Copy of Newspaper Publication

    22 Sep 2026, 11:55AM Symbiotec Pharmalab Limited has informed the Exchange about Copy of Newspaper Publication
  • Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    22 Sep 2026, 2:51PM Audio Recording Of Earnings Conference Call For Analysts And Investors held today September 22, 2026.
  • Symbiotec Pharmalab Q1 net profit up 5.62% at Rs 47.01 cr

    22 Sep 2026, 11:00AM The company reported standalone net profit of Rs 47.01 crore for the quarter ended June 30, 2026 as compared to Rs 44.51 crore in the same period last
  • Symbiotec Pharmalab - Press Release

    21 Sep 2026, 8:01PM Symbiotec Pharmalab Limited has informed the Exchange regarding a press release dated September 21, 2026, titled ""Investor Release of Financial Resul
  • Symbiotec Pharmalab - Investor Presentation

    21 Sep 2026, 7:56PM Symbiotec Pharmalab Limited has informed the Exchange about Investor Presentation
  • Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    21 Sep 2026, 7:51PM Announcement under Regulation 30 (LODR) - Press Release
  • Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Investor Presentation

    21 Sep 2026, 7:48PM Announcement under Regulation 30 (LODR) - Investor Presentation
  • Symbiotec Pharmalab - Outcome of Board Meeting

    21 Sep 2026, 7:39PM Symbiotec Pharmalab Limited has informed the Exchange regarding Outcome of Board Meeting held on September 21, 2026.
  • Symbiotec Pharmalab - Results - Financials For Quarter Ended Jun 30, 2026

    21 Sep 2026, 7:08PM With reference to the captioned subject, this is to inform you that Board Meeting held on September 21, 2026, have inter alia consider and approved th
  • Symbiotec Pharmalab - Outcome of Board Meeting

    21 Sep 2026, 6:45PM Symbiotec Pharmalab Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
  • Symbiotec Pharmalab - Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On Monday, September 21, 202

    21 Sep 2026, 6:33PM Dear Sir / Madam,\r\nWith reference to the captioned subject, this is to inform you that the Board of Directors of the\r\nCompany at its meeting held
  • Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Sep 2026, 6:56PM Dear Sir / Madam,\r\nPursuant to above referred Listing Regulations, we enclose herewith the details of the 'Earnings Conference Call / Analysts Meet'
  • Symbiotec Pharmalab - Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Directors Of Symbiotec Pha

    11 Sep 2026, 4:18PM Symbiotec Pharmalab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2026 ,inter alia, to consider
  • Symbiotec Pharmalab - Updates

    3 Sep 2026, 1:35PM Symbiotec Pharmalab Limited has informed the Exchange regarding 'Update on Intimation under Regulation 8(2) of the Securities and Exchange Board of In
  • Symbiotec Pharmalab - Update On Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition O

    3 Sep 2026, 1:48PM Update on Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
  • Symbiotec Pharmalab has submitted to BSE the Shareholding Pattern for the Period Ended August 31, 2026

    1 Sep 2026, 9:20PM As of August 2026, 33.28% is owned by Indian Promoters and 66.72% by Public. <p align=justify> Institutional holds 48.59% (Insurance Companies 1.07%)
  • Symbiotec Pharmalab - Updates

    1 Sep 2026, 4:36PM Symbiotec Pharmalab Limited has informed the Exchange regarding 'Disclosure under Regulation 30(5) of Securities and Exchange Board of India (Listing
  • Symbiotec Pharmalab - Updates

    1 Sep 2026, 4:30PM Symbiotec Pharmalab Limited has informed the Exchange regarding 'Intimation under Regulation 8(2) of the Securities Exchange Board of India (Prohibiti
  • Symbiotec Pharmalab - Trading Window

    1 Sep 2026, 4:21PM Symbiotec Pharmalab Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio
  • Symbiotec Pharmalab - Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider

    1 Sep 2026, 3:42PM Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
  • Symbiotec Pharmalab - Disclosure Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations

    1 Sep 2026, 3:34PM Disclosure regarding authority to determine materiality of event or information.
  • Symbiotec Pharmalab Ltd. debuts with 0.99% discount at Rs 978.20

    1 Sep 2026, 10:00AM Symbiotec Pharmalab Ltd. makes a weak debut on the bourses with scrip got listed at Rs 978.20 on the Bombay Stock Exchange, a 0.99 per cent discount t
  • Symbiotec Pharmalab - Listing of Equity Shares of Symbiotec Pharmalab Ltd

    1 Sep 2026, 8:18AM Trading Members of the Exchange are hereby informed that effective from September 01, 2026, the Equity Shares of Symbiotec Pharmalab Ltd (Scrip Code:
  • Symbiotec Pharmalab announces launch of initial public offering

    19 Aug 2026, 5:00PM Symbiotec Pharmalab Ltd. has announced public offering of 17783400 shares at a price of Rs 2.00 each for Cash at a Premium of Rs 986.00 per share. The
  • Symbiotec Pharma Ltd

    1 Oct 2026 , 12:09PM Knovea Pharmaceutical, a wholly owned subsidiary of Symbiotec Pharmalab, has entered into a definitive agreement with a leading global pharmaceutical company, granting the partner exclusive rights to commercialise and distribute two dual-chamber vial-based injectable products in the United States.

Key fundamentals

Evaluate the intrinsic value of Symbiotec Pharmalab Ltd stock 

Name March-23
Assets 780.079
Liabilities 780.079
Equity 10.936
Gross Profit 79.465
Net Profit -22.659
Cash From Operating Activities 93.352
NPM(%) -4.02
Revenue 563.586
Expenses 484.121
ROE(%) -1.97

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Symbiotec Pharmalab Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 793.90 -2.32 20.08 645.46 -26.19 0.63
Lotus Eye Hospital and Institute Ltd 113.94 -0.78 1627.71 2351.96 0.39 0.00
Vaishali Pharma Ltd 7.99 -1.36 24.97 14754.60 15.42 0.00
Astec Lifesciences Ltd 714.75 -4.47 0.00 2519.99 -363.14 0.00

Company Info

Our Company wasincorporated as`Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited company, was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025, and a special resolution dated September 12, 2025, passed in the extraordinary general meeting of our Shareholders. Consequently, the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre.Major Events and Milestones:2004- Commenced production of APIs at the Rau Facility2007- Investment by late Rakesh Jhunjhunwala in our Company2009- Received a letter stating that the Rau Facility meets an acceptable state of compliance with cGMP by U.S. FDA2010- Commenced production of APIs including hormone synthesis at the Pithampur Facility- Commissioned a 5 KL biotech plant at the Pithampur Facility- Investment by Franklin Templeton Asset Management (India) Private Limited in our Company2012- Received a letter stating that the Pithampur Facility meets an acceptable state of compliance with the cGMP from the U.S. FDA2013- Investment by Actis Medal Sports Limited in our Company- Commissioned a 35 KL fermentation project at the Pithampur Facility2018- Investment by India Business Excellence Fund- III and Rosewood Investments in our Company2021- Expansion of a sterile plant at the Rau Facility2023- Launched classical fermentation-based APIs at the Pithampur Facility2025- Commissioned a complex injectables facility at the Mhow Facility- Commissioned a 400 KL biomanufacturing facility at the Ujjain Facility

Our Company wasincorporated as`Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited company, was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025, and a special resolution dated September 12, 2025, passed in the extraordinary general meeting of our Shareholders. Consequently, the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre.Major Events and Milestones:2004- Commenced production of APIs at the Rau Facility2007- Investment by late Rakesh Jhunjhunwala in our Company2009- Received a letter stating that the Rau Facility meets an acceptable state of compliance with cGMP by U.S. FDA2010- Commenced production of APIs including hormone synthesis at the Pithampur Facility- Commissioned a 5 KL biotech plant at the Pithampur Facility- Investment by Franklin Templeton Asset Management (India) Private Limited in our Company2012- Received a letter stating that the Pithampur Facility meets an acceptable state of compliance with the cGMP from the U.S. FDA2013- Investment by Actis Medal Sports Limited in our Company- Commissioned a 35 KL fermentation project at the Pithampur Facility2018- Investment by India Business Excellence Fund- III and Rosewood Investments in our Company2021- Expansion of a sterile plant at the Rau Facility2023- Launched classical fermentation-based APIs at the Pithampur Facility2025- Commissioned a complex injectables facility at the Mhow Facility- Commissioned a 400 KL biomanufacturing facility at the Ujjain Facility

Parent Organisation

Symbiotec Pharmalab Ltd.

Founded

20/09/2002

Managing Director

Mr.Anil Satwani

NSE Symbol

SYMBIOTECEQ

FAQ